- Home
- REPL vs DAVA Comparison
REPL vs DAVA Comparison
Compare REPL & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- DAVA
- Stock Information
- Founded
- REPL 2015
- DAVA 2000
- Country
- REPL United States
- DAVA United Kingdom
- Employees
- REPL N/A
- DAVA N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- DAVA EDP Services
- Sector
- REPL Health Care
- DAVA Technology
- Exchange
- REPL Nasdaq
- DAVA Nasdaq
- Market Cap
- REPL 547.0M
- DAVA 503.6M
- IPO Year
- REPL 2018
- DAVA 2018
- Fundamental
- Price
- REPL $9.42
- DAVA $6.32
- Analyst Decision
- REPL Buy
- DAVA Buy
- Analyst Count
- REPL 9
- DAVA 8
- Target Price
- REPL $12.00
- DAVA $18.14
- AVG Volume (30 Days)
- REPL 2.6M
- DAVA 1.4M
- Earning Date
- REPL 11-06-2025
- DAVA 11-11-2025
- Dividend Yield
- REPL N/A
- DAVA N/A
- EPS Growth
- REPL N/A
- DAVA 58.26
- EPS
- REPL N/A
- DAVA 0.25
- Revenue
- REPL N/A
- DAVA $1,015,391,026.00
- Revenue This Year
- REPL N/A
- DAVA N/A
- Revenue Next Year
- REPL N/A
- DAVA $3.81
- P/E Ratio
- REPL N/A
- DAVA $24.78
- Revenue Growth
- REPL N/A
- DAVA 1.07
- 52 Week Low
- REPL $2.68
- DAVA $6.03
- 52 Week High
- REPL $17.00
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- REPL 62.38
- DAVA 30.34
- Support Level
- REPL $8.50
- DAVA $6.03
- Resistance Level
- REPL $9.30
- DAVA $7.36
- Average True Range (ATR)
- REPL 0.61
- DAVA 0.39
- MACD
- REPL -0.14
- DAVA -0.20
- Stochastic Oscillator
- REPL 75.95
- DAVA 7.58
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.